1. Unicycive plans to resubmit NDA for OLC by year-end. 2. Presented positive OLC data showing reduced pill burden at ASN 2025. 3. Company ended Q3 with $42.7 million cash, runway into 2027.
The optimistic announcement about NDA resubmission and positive trial results can enhance investor sentiment and attract buyers, increasing share price. Previous announcements of positive trial data generally led to corresponding stock price increases in biotech firms.
The announcement directly impacts UNCY by advancing its lead product’s approval process, which could lead to significant revenue potential ahead of its planned launch. Hence, investor interest is likely to rise, influencing market perception favorably.
The expected NDA resubmission by year-end could lead to quick market reactions. Historical behavior of stock prices often reflects quick adjustments to regulatory milestones.
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end
- Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders
- Ended Q3 with $42.7 million of cash with expected runway into 2027
LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2025, and provided a business update.
"With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the end of the year, following positive discussions with the FDA and our third-party manufacturing vendor," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "Our focus has always been on enhancing the lives of people with hyperphosphatemia, as evidenced by the promising new data presented at ASN Kidney Week 2025 that showcase OLC's differentiated clinical profile and reduced pill burden compared to currently available phosphate binders. With a cash runway into 2027, we are well positioned to complete the regulatory approval process and prepare for the potential launch of OLC next year, marking significant progress in advancing our mission to deliver improved treatment options for patients on dialysis."
Key Highlights & Upcoming Milestones
Financial Results for the Quarter Ended September 30, 2025
Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2025, compared to approximately $3.1 million for the three months ended September 30, 2024. The decrease in research and development expenses was primarily due to a $235,000 decrease in professional services and drug development costs, partially offset by increases in labor, travel, and other costs of $154,000.
General and Administrative (G&A) expenses were $4.4 million for the three months ended September 30, 2025, compared to $3.2 million for the three months ended September 30, 2024. The increase was primarily due to a $0.6 million increase in labor costs and a $0.5 million increase in consulting and professional services.
Other income was $1.3 million for the three months ended September 30, 2025, compared to other income of $2.2 million for the three months ended September 30, 2024. The decrease was primarily due to the change in fair value of our warrant liability.
Net loss attributable to common stockholders for the three months ended September 30, 2025, was $6.0 million, compared to net loss attributable to common stockholders of $4.1 million for the three months ended September 30, 2024. The increased net loss for the three-month period ended September 30, 2025 was primarily due to increased labor and professional services costs as well as the change in fair value of our warrant liability.
As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has a cash runway into 2027.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
| Unicycive Therapeutics, Inc. | ||||||||
| Balance Sheets | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| As of | As of | |||||||
| December 31, | September 30, | |||||||
| 2024 | 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 26,142 | $ | 42,695 | ||||
| Prepaid expenses and other current assets | 4,806 | 7,592 | ||||||
| Total current assets | 30,948 | 50,287 | ||||||
| Right of use asset, net | 645 | 249 | ||||||
| Property and equipment, net | 75 | 75 | ||||||
| Total assets | $ | 31,668 | $ | 50,611 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,058 | $ | 957 | ||||
| Accrued liabilities | 3,562 | 2,762 | ||||||
| Warrant liability | 18,936 | 9,147 | ||||||
| Operating lease liability - current | 564 | 265 | ||||||
| Total current liabilities | 24,120 | 13,131 | ||||||
| Operating lease liability - long term | 117 | - | ||||||
| Total liabilities | 24,237 | 13,131 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Series A-2 Prime preferred stock, $0.001 par value per share - 21,400 Series A-2 Prime shares authorized at December 31, 2024 and September 30, 2025; 6,150.21 and 2,265 Series A-2 Prime shares issued and outstanding at December 31, 2024, and September 30, 2025, respectively | - | - | ||||||
| Series B-2 preferred stock, $0.001 par value per share - 50,000 Series B-2 shares authorized at December 31, 2024 and September 30, 2025; 3,000 and zero Series B-2 shares issued and outstanding at December 31, 2024, and September 30, 2025, respectively | - | - | ||||||
| Preferred stock: $0.001 par value per share - 10,000,000 shares authorized at December 31, 2024 and September 30, 2025; zero shares issued and outstanding at December 31, 2024, and September 30, 2025 | - | - | ||||||
| Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2024 and September 30, 2025; 11,384,236 and 20,850,363 shares issued and outstanding at December 31, 2024, and September 30, 2025, respectively | 11 | 21 | ||||||
| Additional paid-in capital | 108,690 | 150,617 | ||||||
| Accumulated deficit | (101,270 | ) | (113,158 | ) | ||||
| Total stockholders' equity | 7,431 | 37,480 | ||||||
| Total liabilities and stockholders' equity | $ | 31,668 | $ | 50,611 | ||||
| Unicycive Therapeutics, Inc. | ||||||||
| Statements of Operations | ||||||||
| (in thousands, except for share and per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2024 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 3,045 | $ | 2,964 | ||||
| General and administrative | 3,206 | 4,378 | ||||||
| Total operating expenses | 6,251 | 7,342 | ||||||
| Loss from operations | (6,251 | ) | (7,342 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 416 | 279 | ||||||
| Interest expense | (15 | ) | (15 | ) | ||||
| Change in fair value of warrant liability | 1,754 | 1,067 | ||||||
| Total other income (expenses) | 2,155 | 1,331 | ||||||
| Net loss | (4,096 | ) | (6,011 | ) | ||||
| Dividend to Series B-1 preferred stockholders | - | - | ||||||
| Net loss attributable to common stockholders | $ | (4,096 | ) | $ | (6,011 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.46 | ) | $ | (0.33 | ) | ||
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 8,894,321 | 18,065,389 | ||||||
